LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Lucid Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.38−0.10 (-21.05%)
Close on Oct 19, 2026
- Market cap
- $69.11M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.8026 (−68.02%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Lucid Diagnostics Inc. grew revenue 24.9% to $5.45M over the twelve months to Jun 30, 2026. Free cash flow was -$46.68M.
Revenue
$5.45M
+24.9% vs. a year earlier
Operating income
-$50.69M
TTM Q2 2026
Free cash flow
-$46.68M
FY2025
EPS, diluted
-$0.47
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $69.11M
- P/E ratio
- –
- Price to sales
- 12.69
- Price to book
- 6.32
- Dividend yield
- –
- Free cash flow yield
- -67.55%
Fundamentals
- Revenue
- $5.45M
- Net income
- -$52.26M
- EPS, diluted
- -$0.47
- Free cash flow
- -$46.68M
- Book value per share
- $0.06
- Diluted shares
- 183M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$5.45M+24.9% YoY
Gross profit
–
Operating income
-$50.69M
Net income
-$52.26M
EPS, diluted
-$0.47
Free cash flow
–
Reported periodTrailing twelve months